Vera Therapeutics Inc.
VERAHeld by 9 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying9 funds opened new positions. Next phase3 readout (Atacicept): May 2025. Short interest: 18.8% of float.
Held by 9 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying9 funds opened new positions. Next phase3 readout (Atacicept): May 2025. Short interest: 18.8% of float.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.